X0508 4 2026-02-12 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001724097 ABERNETHY MATT 6027 EDGEWOOD BEND CT. SAN DIEGO CA 92130 0 1 0 0 Chief Financial Officer 0 Common Stock 2026-02-12 4 M 0 2133 0 A 39230 D Common Stock 2026-02-12 4 F 0 1151 123.10 D 38079 D Common Stock 2026-02-13 4 M 0 2241 0 A 40320 D Common Stock 2026-02-13 4 F 0 1210 124.12 D 39110 D Common Stock 2026-02-13 4 M 0 2566 0 A 41676 D Common Stock 2026-02-13 4 F 0 1385 124.12 D 40291 D Common Stock 2026-02-13 4 A 0 9968 0 A 50259 D Common Stock 2026-02-13 4 F 0 5378 124.12 D 44881 D Restricted Stock Unit 2026-02-12 4 M 0 2133 0 D Common Stock 2133 6401 D Restricted Stock Unit 2026-02-13 4 M 0 2241 0 D Common Stock 2241 4484 D Restricted Stock Unit 2026-02-13 4 M 0 2566 0 D Common Stock 2566 2566 D Stock Option 124.12 2026-02-13 4 A 0 44095 0 A 2036-02-13 Common Stock 44095 44095 D Restricted Stock Unit 2026-02-13 4 A 0 7735 0 A Common Stock 7735 7735 D Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. /s/ Darin Lippoldt, Attorney-in-Fact 2026-02-17